Vioxx for migraine
Executive Summary
Merck's COX-2 inhibitor Vioxx (rofecoxib) clears FDA for the acute treatment of migraines in adults March 26. Pfizer has submitted an sNDA for Bextra in the treatment of migraines; the application has an estimated user fee date in September...